U.S. Stem Cell is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.
Revenue (Q1, 2018)
Gross profit (Q1, 2018)
Gross profit margin (Q1, 2018), %
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (31-Oct-2017)
Closing share price (31-Oct-2017)